MAZE at a glance
Maze Therapeutics, Inc. (MAZE, SEC CIK 1842295) filed its latest 10-K annual report on March 25, 2026, a 10-Q quarterly report on August 11, 2026, an 8-K current report on August 17, 2026 and Form 4 insider filings as recently as October 2, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2024 (FY2024), Maze Therapeutics, Inc. (MAZE) reported revenue of $167.5 million and net income of $52.2 million. Diluted EPS was $1.25.
- As of June 30, 2026, 25 institutional investment managers tracked by SignalX reported holding Maze Therapeutics, Inc. (MAZE) shares worth $384.3 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Coloma Jason V on October 1, 2026 of 2,593 shares at $27.02 per share.
- In the last 90 days, MAZE insiders reported 0 open-market purchases ($0) and 32 open-market sales ($6.1M) on Form 4, a net sale of $6.1M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2024
- $167.5M
- 10-K XBRL
- Insiders · 90 days
- 0 buys · 32 sells
- Net −$6.1M
- 13F holders
- 25 funds
- $384.3M · −4 vs prior quarter
- Latest 8-K
- Aug 17, 2026
- Item 7.01 · Item 5.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Risk Factors
- New debt risk triggered by February 2026 Hercules Loan Agreement: $40.0 million funded, secured by substantially all assets except intellectual property
- Liquidity risk: $494.9 million cash, equivalents, and marketable securities projected to fund operations for at least one year
- Regulatory risk: FDA-required additional studies or trial delays could materially increase expenses and defer profitability
- Clinical-development risk: MZE829 and MZE782 remain in early clinical development without demonstrated efficacy or commercial revenue
- Dilution risk: April 2026 offering issued 5,540,000 shares and 850,000 pre-funded warrants for approximately $144.6 million net proceeds
AI summary of the MAZE 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 7.01: Regulation FD Disclosure
- Exhibit 99.1 furnished under Regulation FD, not treated as filed under Exchange Act Section 18
- Exhibit excluded from Securities Act Sections 11 and 12(a)(2) liability
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Board additions: Paula A. Johnson and Sophie Kornowski appointed as Class III and Class I directors, respectively
- Dr. Kornowski joins audit and compensation committees, strengthening biopharma, investment and business-development expertise
Item EX-99.1: Item EX-99.1
- Paula Johnson and Sophie Kornowski appointed to Maze’s Board, strengthening clinical, biopharmaceutical, partnering, and M&A expertise
- MZE829 additional AMKD data expected in late 2026 or early 2027
Item EX-99.1: Item EX-99.1
- Q2 net loss $44.7M, or $0.76 per share, versus $33.7M and $0.77 in Q2 2025
- Cash, equivalents and marketable securities $494.9M, supporting operations into 2029 under current plans
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 financial results for quarter ended June 30, 2026
- Press release issued August 11, 2026
Item 5.07: Submission of Matters to a Vote of Security Holders
- 89.75% shareholder participation provided a strong quorum for the 2026 annual meeting
- Jason Coloma and Neil Kumar elected as Class I directors through the 2029 annual meeting
AI summaries of MAZE 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for MAZE
Don't miss the next MAZE filing
- Alerts as it files. A push when MAZE files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut MAZE, by share count.
- Ask anything. An AI agent that reads every MAZE filing and answers with sources.
MAZE alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Coloma Jason V | Sell | Oct 1, 2026 | 2,593 | $27.02 |
| Bernstein Harold | M | Oct 1, 2026 | 16,141 | $10.42 |
| Bernstein Harold | M | Oct 1, 2026 | 16,141 | - |
| Bernstein Harold | Sell | Oct 1, 2026 | 16,141 | $26.93 |
| Coloma Jason V | Sell | Oct 1, 2026 | 31,908 | $27.02 |
| Dandekar Atul | M | Sep 29, 2026 | 7,500 | $10.42 |
| Dandekar Atul | M | Sep 29, 2026 | 7,500 | - |
| Dandekar Atul | Sell | Sep 29, 2026 | 7,500 | $27.06 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $167.5M | - |
| Operating Income | - | $57.6M | -$142.9M |
| Net Income | - | $52.2M | -$131.1M |
| Op. Margin | - | 34.4% | - |
| Net Margin | - | 31.2% | - |
| Balance Sheet | |||
| Total Assets | - | $240.5M | $397.1M |
| Equity | -$373.8M | -$311.2M | $355.0M |
| ROE | - | -16.8% | -36.9% |
| Per Share | |||
| EPS | - | $1.25 | $-3.05 |
| Cash Flow | |||
| Operating CF | - | $76.0M | -$111.9M |
| CapEx | - | $1.1M | $794K |
Source: XBRL data in Maze Therapeutics, Inc. (MAZE)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate MAZE share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 25 | $384.3M |
| Q1 2026 | 29 | $284.2M |
| Q4 2025 | 25 | $349.2M |
| Q3 2025 | 19 | $178.0M |
| Q2 2025 | 14 | $53.5M |
| Q1 2025 | 13 | $47.3M |
- BlackRock+932.4K (+36%)
- JPMorgan Chase & Co+905.6K (+1549%)
- State Street Corp+360.8K (+57%)
- Vanguard Capital Management LLC+342.6K (+24%)
- Vanguard Portfolio Management LLC+197.6K (+101%)
- Morgan Stanley−69.7K (-34%)
- Invesco Ltd−58.0K (-67%)
- D.E. Shaw & Co−33.6K (-74%)
- Raymond James Financial−3.0K (-4%)
- AQR Capital Management−784 (-3%)
- Millennium Management−29.9K
- Blackstone Group−25.0K
- Renaissance Technologies LLC−15.8K
- Mangrove Partners−6.7K
Source: 13F-HR filings on SEC EDGAR (aggregated from 125 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
MAZE filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Oct 1, 2026 | - | - | - |
| 4 | Sep 8, 2026 | - | - | - |
| 4 | Sep 4, 2026 | - | - | - |
| 4 | Sep 4, 2026 | - | - | - |
| 4 | Sep 4, 2026 | - | - | - |
| 4 | Sep 4, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Aug 31, 2026 | - | - | - |
| 8-K | Aug 17, 2026 | - | Analysis | - |
| 4 | Aug 17, 2026 | - | - | - |
| 4 | Aug 17, 2026 | - | - | - |
| 4 | Aug 14, 2026 | - | - | - |
| 8-K | Aug 11, 2026 | - | Analysis | - |
| 10-Q | Aug 11, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Aug 5, 2026 | - | - | - |
| 4 | Jul 31, 2026 | - | - | - |
| SC 13G | Jul 29, 2026 | - | - | |
| 4 | Jul 2, 2026 | - | - | - |
| 4 | Jul 2, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ADMA · ADMA BIOLOGICS, INC.Biological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AMGN · AmgenBiological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
MAZE SEC filings: frequently asked questions
Are MAZE insiders buying or selling?
In the last 90 days, Maze Therapeutics, Inc. (MAZE) officers, directors and 10% owners reported no open-market purchases and 32 open-market sales worth $6.1 million by 4 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold MAZE stock?
As of June 30, 2026, the largest Maze Therapeutics, Inc. (MAZE) holders among the 13F filers tracked by SignalX were BlackRock ($104.5 million), Vanguard Capital Management LLC ($53.1 million), Alphabet Inc ($41.4 million), FMR LLC (Fidelity) ($31.5 million), State Street Corp ($29.8 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was MAZE's revenue in fiscal year 2024?
For the fiscal year ended December 31, 2024 (FY2024), Maze Therapeutics, Inc. (MAZE) reported revenue of $167.5 million and net income of $52.2 million. Diluted EPS was $1.25. The figures come from the XBRL data in the 10-K.
What did MAZE report in its latest 8-K?
Maze Therapeutics, Inc. (MAZE) filed an 8-K on August 17, 2026 reporting Item 7.01 (Regulation FD Disclosure) and Item 5.02 (Departure/Appointment of Directors or Principal Officers). Exhibit 99.1 furnished under Regulation FD, not treated as filed under Exchange Act Section 18.
What are the latest MAZE SEC filings?
Maze Therapeutics, Inc. (MAZE) filed its latest 10-K annual report on March 25, 2026, a 10-Q quarterly report on August 11, 2026, an 8-K current report on August 17, 2026 and a Form 4 insider filing on October 2, 2026.
What is MAZE's SEC CIK number?
Maze Therapeutics, Inc. (MAZE)'s SEC Central Index Key (CIK) is 1842295. EDGAR lists every MAZE filing under that number.
Ask anything about MAZE
The research agent reads MAZE's filings, financials, insider trades and 13F holders, then answers with sources.